RÉSUMÉ
Group B Streptococcus (GBS) disease in neonates occurs in two forms: early-onset disease (EOD), (day 0-6), and late-onset disease (LOD), (day 7-90). This review investigates that risk-based intrapartum screening and antibiotics have reduced the incidence of EOD, but not LOD, in Denmark. No clinical or laboratory tests can rule out GBS disease at symptom onset. Thus, a high proportion of uninfected infants receive antibiotics, although this varies widely, and may be reduced by strategies of antibiotic stewardship. A future GBS vaccine for pregnant women may potentially reduce disease burden and antibiotic exposure.
Sujet(s)
Antibactériens , Infections à streptocoques , Streptococcus agalactiae , Humains , Infections à streptocoques/diagnostic , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/traitement médicamenteux , Nouveau-né , Streptococcus agalactiae/isolement et purification , Antibactériens/usage thérapeutique , Antibactériens/administration et posologie , Femelle , Grossesse , Danemark/épidémiologie , Complications infectieuses de la grossesse/diagnostic , Complications infectieuses de la grossesse/microbiologie , Complications infectieuses de la grossesse/prévention et contrôle , Complications infectieuses de la grossesse/traitement médicamenteux , Nourrisson , Vaccins antistreptococciques/administration et posologie , Transmission verticale de maladie infectieuse/prévention et contrôleRÉSUMÉ
In Denmark, severe acute respiratory syndrome coronavirus 2 antibodies were assessed in a cross-sectional study among 1033 children visiting pediatric departments and 750 blood donors in June 2020, using a point-of-care test. Antibodies were detected in 17 children (1.6%) and 15 blood donors (2.0%) (P = 0.58). In conclusion, children and adults were infected to a similar low degree.